A newly approved National Cancer Institute-funded clinical trial aims to improve survival for head and neck cancer patients ...
Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage ...
Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination ...
For women, early signs of cervical cancer can feel harmless, a change in discharge, mild discomfort or simply feeling “off” ...
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in untreated metastatic triple-negative breast cancer patients.
KAREN Huff thought she had just put on a bit of holiday weight – but for the Dublin mum-of-two, the stubborn belly wasn’t ...
GlobalData on MSN
Genmab reports top line results in Phase III DLBCL trial
Genmab plans to present full results at an upcoming medical meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results